Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Free Radic Biol Med. 2012 Dec 1;53(11):2178-87. doi: 10.1016/j.freeradbiomed.2012.09.028. Epub 2012 Sep 26.

Redox regulation of the epigenetic landscape in cancer: a role for metabolic reprogramming in remodeling the epigenome.

Author information

  • 1Department of Radiation Oncology, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA 90027, USA.

Abstract

Cancer arises from normal cells that acquire a series of molecular changes; however, the founding events that create the clonogens from which a tumor will arise and progress have been the subject of speculation. Through the efforts of several generations of cancer biologists it has been established that the malignant phenotype is an amalgamation of genetic and metabolic alterations. Numerous theories have suggested that either, or both, of these elements might serve as the impetus for cancer formation. Recently, the epigenetic origins of cancer have been suggested as an additional mechanism giving rise to the malignant phenotype. When the discovery that the enzymes responsible for initiating and perpetuating epigenetic events is linked to metabolism by their cofactors, a new paradigm for the origins of cancer can be created. Here, we summarize the foundation of such a paradigm on the origins of cancer, in which metabolic alterations create an epigenetic progenitor that clonally expands to become cancer. We suggest that metabolic alterations disrupt the production and availability of cofactors such as S-adenosylmethionine, α-ketoglutarate, NAD(+), and acetyl-CoA to modify the epigenotype of cells. We further speculate that redox biology can change epigenetic events through oxidation of enzymes and alterations in metabolic cofactors that affect epigenetic events such as DNA methylation. Combined, these metabolic and redox changes serve as the foundation for altering the epigenotype of normal cells and creating the epigenetic progenitor of cancer.

Copyright © 2012 Elsevier Inc. All rights reserved.

PMID:
23022407
[PubMed - indexed for MEDLINE]
PMCID:
PMC3508253
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk